[
  {
    "ts": "2025-12-16T12:00:00+00:00",
    "headline": "Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)",
    "summary": "Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD",
    "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "57994114-386d-3307-9983-571024ec9741",
      "content": {
        "id": "57994114-386d-3307-9983-571024ec9741",
        "contentType": "STORY",
        "title": "Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)",
        "description": "",
        "summary": "Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD",
        "pubDate": "2025-12-16T12:00:00Z",
        "displayTime": "2025-12-16T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b",
          "originalWidth": 440,
          "originalHeight": 386,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Km.iDUymrS8htWjo9.aZZg--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b.cf.webp",
              "width": 440,
              "height": 386,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ND76FpkFurDCgVBykGeoxg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADAG"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]